Skip to main content
SpringerLink
Log in

Inhibition of monoamine oxidases by haloperidol and its metabolites: pharmacological implications for the chemotherapy of schizophrenia

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

The effect of haloperidol and its metabolites on human platelet monoamine oxidase B (MAO-B) and human placenta monoamine oxidase A (MAO-A) in vitro has been investigated. We found that 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-pyridinium (HP+), 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydropyridine (HTP) and 4-chlorophenyl-1,2,3,6-tetrahydropyridine (CPTP) are potent inhibitors of MAO. HP+ appeared to be a reversible, uncompetitive and selective MAO-B inhibitor with a Ki of 0.83 µM. HTP was found to be an irreversible, uncompetitive and selective MAO-B inhibitor (Ki of 1.84 µM). CPTP inhibits both MAO-A and MAO-B. Some other haloperidol metabolites, i.e. 4-(4-chlorophenyl)-4-hydroxypyridine (CPHP), 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydropyridine N-oxide (HTPNO) and reduced haloperidol (RHAL), do not inhibit MAO to any appreciable degree at concentrations up to 100 µM. The results suggest that haloperidol metabolites may contribute to the reduction of platelet MAO-B activity in schizophrenic patients undergoing neuroleptic chemotherapy. An examination of the literature reveals that schizophrenic patients with low platelet MAO activity exhibit a strong association with the use of haloperidol. Other possible pharmacological implications of the inhibition of MAO activity are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Arnett CD, Fowler JS, MacGregor RR et al. (1987) Turnover of brain monoamine oxidase measured in vivo by positron emission tomography using L-[14C]-deprenyl. J Neurochem 49:522–525

    Google Scholar 

  • Baron M, Gruen R, Levitt M, Kane J (1982) Neuroleptic drug effect on platelet monoamine oxidase and plasma amine oxidase in schizophrenia. Psychiatry Res 7:179–187

    Google Scholar 

  • Baron M, Levitt M, Gruen R, Kane J, Asnis L (1984) Platelet monoamine oxidase activity and genetic vulnerability to schizophrenia. Am J Psychiatry 141:836–842

    Google Scholar 

  • Becker RE, Shaskan EG (1977) Platelet monoamine oxidase activity in schizophrenic patients. Am J Psychiatry 134:512–517

    Google Scholar 

  • Belmaker RH (1984) The lesions of platelet monoamine oxidase. Psychol Med 14:249–253

    Google Scholar 

  • Breier A, Hitzemann RJ, Hirschowitz J, Garver DL (1981) Kinetic analysis of platelet monoamine oxidase in chronic schizophrenia. Life Sci 28:1947–1951

    Google Scholar 

  • Buckman TD, Kling A, Sutphin MS, Steinberg A, Eiduson S (1990) Platelet glutathione peroxidase and monoamine oxidase activity in schizophrenics with CT scan abnormalities: relation to psychosocial variables. Psychiatry Res 31:1–14

    Google Scholar 

  • Chojnacki M, Kralik P, Allen RH, Ho BT, Schoolar JC, Smith RC (1981) Neuroleptic-induced decrease in platelet MAO activity of schizophrenic patients. Am J Psychiatry 138:838–840

    Google Scholar 

  • Davis BA, Yu PH, Carlson K, O'Sullivan K, Boulton AA (1982) Plasma levels of phenylacetic acid, and platelet monoamine oxidase activity in schizophrenic and other patients. Psychiatry Res 6:97–105

    Google Scholar 

  • Del Vecchio M, Maj M, D'Ambrosio A, Kemali D (1983) Low platelet MAO activity in chronic schizophrenics: a long term effect of neuroleptic treatment? Psychopharmacology 79:177–179

    Google Scholar 

  • DeLisi LE, Wise CD, Bridge TP, Rosenblatt JE, Wagner RL, Morihisa J, Karson C, Potkin SG, Wyatt RJ (1981) A probable neuroleptic effect on platelet monoamine oxidase in chronic schizophrenic patients. Psychiatry Res 4:95–107

    Google Scholar 

  • Dixon M, Webb EC (1979) Enzymes, Longman, London, pp 47–206

    Google Scholar 

  • Fang J, Gorrod JW (1991) Dehydration is the first step in the biotransformation of haloperidol to its pyridinium metabolite. Toxicol Lett 59:117–123

    Google Scholar 

  • Fang J, Gorrod JW (1993) An HPLC system for the analysis of haloperidol and seven of its metabolites in microsomal preparations. J Chromatogr 614:267–273

    Google Scholar 

  • Fang J, Gorrod JW, Kajbaf M, Lamb JH, Naylor S (1992) Investigation of the neuroleptic drug haloperidol and its metabolites using tandem mass spectrometry. Int J Mass Spectrometry Ion Proc 122:121–131

    Google Scholar 

  • Fang J, Rosen R, Gorrod JW (1994a) Investigation of fifty three heterocyclic amines as potential substrate and inhibitors of monoamine oxidase. Pharm Sci Commun (in press)

  • Fang J, Zuo DM, Yu PH (1994b) Neurotoxicity of haloperidol and its metabolites towards cultured dopamine neuroblastoma cells. Trans Am Soc Neurochem 25:193

    Google Scholar 

  • Forsman A, Larsson M (1978) Metabolism of haloperidol. Curr Ther Res 24:567–568

    Google Scholar 

  • Friedhoff AJ, Miller JC, Weisenfreund J (1978) Human platelet MAO in drug-free and medicated schizophrenic patients. Am J Psychiatry 135:952–955

    Google Scholar 

  • Friedman E, Shoprin B, Salthananthan G, Gershon S (1974) Blood platelet monoamine oxidase activity in psychiatric patients. Am J Psychiatry 135:952–955

    Google Scholar 

  • Gattaz WF, Kasper S, Propping P, Friedl W, Beckmann H (1981) Low platelet MAO activity and schizophrenia: sex differences. Acta Psychiat Scand 64:167–174

    Google Scholar 

  • Gibb C, Willoughby J, Glover V, Sandler M, Testa B, Jenner P, Marsden CD (1987) Analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as monoamine oxidase substrates: a second ring is not necessary. Neurosci Lett 76:316–322

    Google Scholar 

  • Giller E, Hall H, Reubens L, Wojciechoswki J (1984) Haloperidol inhibition of monoamine oxidase in vivo and in vitro. Biol Psychiatry 19:517–523

    Google Scholar 

  • Gorrod JW, Fang J (1993) On the metabolism of haloperidol. Xenobiotica 23:495–508

    Google Scholar 

  • Ho BT, Smith RC, Kralik P, Allen R, Schoolar J, Khan M, DeJohn C (1982) Effects of neuroleptics on platelet monoamine oxidase activity. Biol Psychiatry 17:885–895

    Google Scholar 

  • Igarashi K, Castagnoli N Jr (1992) Determination of the pyridinium metabolite derived from haloperidol in brain tissue, plasma and urine by high-performance liquid chromatography with fluorescence detection. J Chromatogr 579:277–283

    Google Scholar 

  • Jackman HL, Meltzer HY (1980) Factors affecting determination of platelet monoamine oxidase activity. Schizophr. Bull 6:259–264

    Google Scholar 

  • Kemali K, Maj M, Ariano MG, Salvati A (1985) Platelet monoamine-oxidase activity in schizophrenia. L'Encephale 6:31–34

    Google Scholar 

  • Leelavathi DE, Smith RC (1980) Chronic neuroleptic and brain monoamine oxidase activity. Biol Psychiatry 15:479–484

    Google Scholar 

  • Maj M, Grazia A, Pirozzi R, Salvati A, Kemali D (1984) Platelet monoamine oxidase activity in schizophrenia: relationship to family history of the illness and neuroleptic treatment. J Psychiat Res 18:131–137

    Google Scholar 

  • Maj M, Arena F, Galderisi S, Starace F, Kemali D (1986) Factors associated with decreased platelet MAO activity in chronic schizophrenics. Prog Neuropsychopharmacol Biol Psychiatry 11:79–86

    Google Scholar 

  • Mann J, Thomas KM (1979) Platelet monoamine oxidase activity in schizophrenia: relationship to disease, treatment, institutionalization and outcome. Br J Psychiatry 134:366–371

    Google Scholar 

  • Meltzer HY, Duncavage MB, Jackman H, Arora RC, Tricou BJ, Young M (1982) Effect of neuroleptic drugs on platelet monoamine oxidase in psychiatric patients. Am J Psychiatry 139:1242–1248

    Google Scholar 

  • Murphy DL, Kalin NH (1980) Biological and behavioral consequences of alterations in monoamine oxidase activity. Schizophr Bull 6:355–367

    Google Scholar 

  • Murphy DL, Wyatt RJ (1972) Reduced monoamine oxidase activity in blood platelet from schizophrenic patients. Nature 238:225–226

    Google Scholar 

  • Murphy DL, Belmaker R, Wyatt RJ (1974) Monoamine oxidase in schizophrenia and other behavioral disorders. J Psychiat Res 11:221–247

    Google Scholar 

  • Murphy DL, Donnelly CH, Miller L, Wyatt RJ (1977) Platelet monoamine oxidase in chronic schizophrenia. Arch Gen Psychiatry 33:1377–1381

    Google Scholar 

  • Oida T, Terauchi Y, Yoshida K, Kagemoto A, Sekine Y (1989) Use of antisera in the isolation of human specific conjugate of haloperiodol. Xenobiotica 19:781–793

    Google Scholar 

  • O'Reilly R, Davis BA, Durden DA, Thorpe L, Machnee H, Boulton AA (1991) Plasma phenylethylamine in schizophrenic patients. Biol Psychiatry 30:145–150

    Google Scholar 

  • Orsulak PJ, Schildkraut JJ, Schatzberg AF, Herzog JM (1978) Differences in platelet monoamine oxidase activity in subgroups of schizophrenic and depressive disorders. Biol Psychiatry 13:637–647

    Google Scholar 

  • Owen F, Bourne R, Crow TJ, Johnstone EC, Bailey AR, Hershon HI (1976) Platelet monoamine oxidase in schizophrenia. Arch Gen Psychiatry 33:1370–1373

    Google Scholar 

  • Owen F, Broune RC, Crow TJ, Fadhli AA, Johnstone EC (1981) Platelet monoamine oxidase activity in acute schizophrenia: relationship to symptomatology and neuroleptic medication. Br J Psychiatry 139:16–22

    Google Scholar 

  • Paik IH, Lee C, Kim CE (1988) Platelet MAO in schizophrenics: relationship to symptomatology and neuroleptics. Biol Psychiatry 23:89–93

    Google Scholar 

  • Paterson IA, Juorio AV, Boulton AA (1990) 2-Phenylethylamine: a modulator of catecholamine transmission in the mammalian central nervous system? J Neurochem 55:1827–1837

    Google Scholar 

  • Perenyi A, Bagdy G, Arato M, Frecska E (1984) Biochemical markers in study of clinical effects and extrapyramidal side effects of neuroleptics. Psychiatry Res 13:119–127

    Google Scholar 

  • Potkin SG, Karoum F, Chuang L, Cannon-Spoor HE, Phillips I, Wyatt RJ (1979) Phenylethylamine in paranoid chronic schizophrenia. Science 206:470–471

    Google Scholar 

  • Reveley MA, Reveley AM, Clifford CA, Murray RM (1983) Genetics of platelet MAO activity in discordant schizophrenic and normal twins. Br J Psychiatry 142:560–565

    Google Scholar 

  • Sahai S, Arora RC, Meltzer HY (1981) Effect of chlorpromazine treatment on monoamine oxidase activity in platelet isolated by the Corash method. Psychiatry Res 5:111–114

    Google Scholar 

  • Salach JI, Singer TP, Castagnoli N Jr, Trevor A (1984) Oxidation of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidase A and B and suicide inactivation of the enzymes by MPTP. Biochem Biophys Res Commun 125:831–835

    Google Scholar 

  • Sandler M, Reveley MA, Glover V (1981) Human platelet monoamine oxidase activity in health and disease: a review. J Clin Pathol 34:292–302

    Google Scholar 

  • Soudijn W, Van Wijngaarden I, Allewijn F (1967) Distribution, excretion and metabolism of neuroleptics of the butyrophenone type: part I. excretion and metobolism of haloperidol and nine related butyrophenone-derivatives in the Wistar rat. Eur J Pharmacol 1:47–57

    Google Scholar 

  • Subramanyam B, Rollema H, Woolf T, Castagnoli N Jr (1990) Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats. Biochem Biophys Res Commun 166:238–244

    Google Scholar 

  • Subramanyam B, Woolf T, Castagnoli N Jr (1991) Studies on the in vitro conversion of haloperidol to a potentially neurotoxic pyridinium metabolite. Chem Res Toxicol 4:123–128

    Google Scholar 

  • Takahashi S, Yamane H, Tani N (1975) Reduction of blood platelet monoamine oxidase activity in schizophrenic patients on phenothiazines. Folia Psychiatr Neurol Japon 29:207–214

    Google Scholar 

  • White HL, McLeod MN, Davidson JRT (1976) Platelet monoamine oxidase activity in schizophrenia. Am J Psychiatry 133:1191–1193

    Google Scholar 

  • Wyatt RJ, Murphy DL (1976) Low platelet monoamine oxidase activity and schizophrenia. Schizophr Bull 2:77

    Google Scholar 

  • Wyatt RJ, Potkin SG, Murphy DL (1979) Platelet monoamine oxidase activity in Schizophrenia: a review of the data. Am J Psychiatry 136:377–385

    Google Scholar 

  • Yu PH (1981) Studies on the pargyline binding site of different types of monoamine oxidases. Can J Biochem 59:30–37

    Google Scholar 

  • Yu PH (1986) Monoamine oxidase. In: Boulton AA, Baker GB, Yu PH (eds) Neuromethods; neurotransmitter enzymes, Humana Press. Clifton, N.J. vol. V. pp 235–272

    Google Scholar 

  • Yu PH, Bowen R, Carlson K, O'Sullivan K, Boulton AA (1982) Comparison of some biochemical properties of platelet monoamine oxidase in mentally disordered and healthy individuals. Psychiatry Res 6:107–121

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neuropsychiatry Research Unit, Department of Psychiatry, University of Saskatchewan, S7N 0W0, Saskatoon, Saskatchewan, Canada

    J. Fang, P. H. Yu & A. A. Boulton

  2. Department of Pharmacy, King's College, University of London, Manresa Road, SW3 6LX, Chelsea, London, UK

    J. W. Gorrod

Authors
  1. J. Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. H. Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. A. Boulton
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. W. Gorrod
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fang, J., Yu, P.H., Boulton, A.A. et al. Inhibition of monoamine oxidases by haloperidol and its metabolites: pharmacological implications for the chemotherapy of schizophrenia. Psychopharmacology 118, 206–212 (1995). https://doi.org/10.1007/BF02245841

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02245841

Key words

Search

Navigation